According to a recent LinkedIn post from Supira Medical Inc, the company’s SUPPORT II Pivotal Study for high-risk percutaneous coronary intervention (HRPCI) has begun enrolling subjects at multiple U.S. centers. The post cites early participation from Montefiore Health System, Hillcrest HealthCare System’s Oklahoma Heart Institute, and UC Davis Health, and attributes this progress to collaboration with several principal investigators and advisors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post also describes the Supira System as featuring a low-profile 10Fr introducer and delivering up to 5.5 liters per minute of continuous flow, aided by dual sensors for real-time pressure monitoring. It emphasizes that the Supira System remains an investigational device and is not approved for sale in the U.S. or globally.
For investors, the early momentum in the SUPPORT II Pivotal Study suggests that Supira Medical is advancing its clinical validation efforts in the mechanical circulatory support segment of interventional cardiology. Successful progression of this pivotal trial could be a key step toward future regulatory submissions and potential commercialization, though timelines and outcomes remain uncertain at this stage.
Engagement from multiple academic and regional health systems, along with recognized clinical leaders, may indicate growing clinical interest in alternative HRPCI support technologies. If trial results ultimately demonstrate safety and efficacy, Supira Medical could strengthen its competitive position in a market currently served by established hemodynamic support devices, potentially expanding its long-term addressable market opportunity.